Purple Biotech (Israel) Performance
| KTOV Stock | ILA 7.20 0.20 2.70% |
The company holds a Beta of -0.57, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Purple Biotech are expected to decrease at a much lower rate. During the bear market, Purple Biotech is likely to outperform the market. At this point, Purple Biotech has a negative expected return of -0.56%. Please make sure to check Purple Biotech's potential upside, kurtosis, and the relationship between the maximum drawdown and skewness , to decide if Purple Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Purple Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 5.2 M | |
| Total Cashflows From Investing Activities | -449 K |
Purple |
Purple Biotech Relative Risk vs. Return Landscape
If you would invest 1,400 in Purple Biotech on September 13, 2024 and sell it today you would lose (680.00) from holding Purple Biotech or give up 48.57% of portfolio value over 90 days. Purple Biotech is generating negative expected returns and assumes 15.9988% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Purple on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Purple Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Purple Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Purple Biotech, and traders can use it to determine the average amount a Purple Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0348
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KTOV |
Estimated Market Risk
| 16.0 actual daily | 96 96% of assets are less volatile |
Expected Return
| -0.56 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Purple Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Purple Biotech by adding Purple Biotech to a well-diversified portfolio.
Purple Biotech Fundamentals Growth
Purple Stock prices reflect investors' perceptions of the future prospects and financial health of Purple Biotech, and Purple Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Purple Stock performance.
| Return On Equity | -0.92 | |||
| Return On Asset | -0.0915 | |||
| Operating Margin | (7.54) % | |||
| Shares Outstanding | 172.11 M | |||
| Price To Earning | (364.21) X | |||
| Price To Book | 1.27 X | |||
| Price To Sales | 16.36 X | |||
| Revenue | 1000 K | |||
| EBITDA | (6.26 M) | |||
| Cash And Equivalents | 63.01 M | |||
| Cash Per Share | 0.40 X | |||
| Total Debt | 117 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.35 X | |||
| Cash Flow From Operations | (5.58 M) | |||
| Earnings Per Share | (0.17) X | |||
| Total Asset | 14.72 M | |||
About Purple Biotech Performance
By analyzing Purple Biotech's fundamental ratios, stakeholders can gain valuable insights into Purple Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Purple Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Purple Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. KITOV PHARMA operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.Things to note about Purple Biotech performance evaluation
Checking the ongoing alerts about Purple Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Purple Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Purple Biotech generated a negative expected return over the last 90 days | |
| Purple Biotech has high historical volatility and very poor performance | |
| Purple Biotech has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1000 K. Net Loss for the year was (5.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Purple Biotech has accumulated about 63.01 M in cash with (5.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4. |
- Analyzing Purple Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Purple Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Purple Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Purple Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Purple Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Purple Biotech's stock. These opinions can provide insight into Purple Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Purple Stock analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |